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Global spread and evolutionary links of an epidemic Clostridium difficile strain (PCR-ribotype
027) have been noted in recent decades. However, in Japan, no outbreaks caused by type 027
have been reported to date. A total of 120 C. difficile isolates from patients at 15 hospitals
during non-outbreak seasons between 2011 and 2013 as well as 18 and 21 isolates collected
from two hospitals in 2010 and 2009, respectively, in outbreak periods in Japan, were
examined. Among these 120 isolates, Japan-ribotypes smz and ysmz (subtype variant of smz)
were the most predominant (39.2 %) followed by Japan-ribotype trf (15.8 %). Types smz/ysmz
and trf were also concurrently predominant at two hospitals in the outbreak settings. Out of the
five binary-toxin-positive isolates observed, only one was PCR-ribotype 027 and another PCR-
ribotype 078.Type smz was later found to correspond to PCR-ribotype 018. High rates of
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resistance against gatifloxacin, moxifloxacin, erythromycin and clindamycin were observed in the
PCR-ribotype 018 isolates. Interestingly, all trf isolates were toxin-A-negative, toxin-B-positive,
but they did not correspond to PCR-ribotype 017, thus being assigned a new ribotype (PCR-
ribotype 369). In conclusion, PCR-ribotypes 018 (smz) and 369 (trf) were identified as major
circulating strains in both outbreak and non-outbreak settings in Japan. Given their
epidemiological relevance, molecular investigations are warranted to clarify potential evolutionary
links with related strains found elsewhere, such as PCR-ribotypes 018 and 017 from Europe
and North America.
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Accepted 30 July 2015
INTRODUCTION
Clostridium difficile is well known as the leading cause of
healthcare-associated infectious diarrhoea. The global
spread of a hypervirulent strain, PCR-ribotype 027 (BI/
NAP1/027), that is resistant to fluoroquinolones has been
reported in recent decades, and its influence on both the
incidence of C. difficile infection (CDI) and the severity
of CDI has widely been acknowledged (Miller et al.,
2010; Wilcox et al., 2012; He et al., 2013; Davies et al.,
2014). Similarly, PCR-ribotype 078 was reported to be
another hypervirulent strain and linked with a severe
disease (Goorhuis et al., 2008; Walker et al., 2013).
A surveillance study in 34 European countries indicated
that infections by PCR-ribotypes 018 and 056 were signifi-
cantly associated with complicated disease outcome (Bauer
et al., 2011). PCR-ribotype 018 and ribotype 356, of which
the fingerprinting profile is closely related to that of 018,
were reported to be predominant and associated with mul-
tiple antimicrobial resistance in Italy (Freeman et al., 2015;
Spigaglia et al., 2010). Also, PCR-ribotype 018 was reported
to be a predominant strain in Korea (Han et al., 2014).
On the other hand, the emergence of toxin-A-negative,
toxin-B-positive (A2B+) C. difficile has been noted in the
Netherlands, Ireland, Poland, Korea, China and Argentina
(Kuijper et al., 2001; Drudy et al., 2007; Pituch et al., 2011;
Shin et al., 2008; Goorhuis et al., 2009; Hawkey et al. 2013),
and in some of these reports the resistance of PCR-ribotype
017 (A2B+) to clindamycin was documented (Kuijper
et al., 2001; Goorhuis et al., 2009; Pituch et al., 2011).
It was reported that differences in strain types have an
impact not only on epidemiology but also on course of
treatment and laboratory diagnosis (Louie et al., 2011; Ten-
over et al., 2010). Hence, a number of reports have
emphasized the importance of local surveillance of both
endemic and epidemic strains.
In Japan, we have reported that a specific C. difficile type
strain, PCR-ribotype smz, has been dominant at numerous
hospitals since the 1990s (Kato et al., 2001a, 2010; Sawabe
et al., 2007; Iwashima et al., 2010). In addition, frequent
isolation of A2B+C. difficile has been noted at some
Japanese hospitals (Komatsu et al., 2003; Sato et al.,
2004; Kato et al., 2010). In the present study, we analysed
C. difficile isolates collected from 15 different hospitals
between 2011 and 2013 in non-outbreak settings, and
from outbreaks that occurred independently in 2009 and
2010 at two hospitals in Japan.
METHODS
Bacterial strains. A total of 120 C. difficile isolates recovered from
sporadic CDI cases at 15 medical facilities in 13 prefectures in Japan
(hospitals A to O) in non-outbreak settings during a two-year period
from April 2011 to March 2013, were examined. Between five and 10
CDI patients were chosen randomly at each hospital, and informed
consent was obtained from each of them. Among the 15 hospitals
investigated, hospitals L and N were previously reported as outbreak
settings in 2010 and 2009, respectively, based on the incidence figures
of new cases, which was more than double the averages in the pre-
vious period at these sites. In total, 21 and 18 isolates from hospital L
and hospital N in outbreak periods, respectively, were available for
this study. This study was approved by the Ethics Board of National
Institute of Infectious Diseases (NIID), Tokyo, Japan.
PCR detecting the toxin genes and typing analysis. The presence
of the non-repeating sequences of the toxin B gene (tcdB) and the
repeating sequences of the toxin A gene (tcdA) was examined by PCR
as described previously (Kato et al., 2005). Detection of the gene
encoding the binding component of binary toxin (CDT) was per-
formed as described by Stubbs et al. (2000). Typing analysis by PCR
ribotyping was performed as described by Stubbs et al. (1999) with
minor modifications (Kato et al., 2010). A new PCR ribotype was
identified when two or more band differences were found from
previously identified patterns (Kato et al., 2010). Isolates identified as
types smz, ysmz and trf by the Japan ribotyping scheme in NIID were
subject to PCR ribotyping at the Liverpool Clinical Laboratories
(LCL, Royal Liverpool and Broadgreen University Hospitals, Liver-
pool, UK). slpA sequence typing was carried out as described pre-
viously (Kato et al., 2010). When compared with the reference
libraries, isolates were assigned to distinct major groups if they had 20
or more differing amino acids, but were considered as subtypes when
such differences were restricted to less than 20 (Kato et al., 2010).
Abbreviations: CDI, Clostridium difficile infection; CDT, binary toxin;
LCL, Liverpool Clinical Laboratories
The GenBank/EMBL/DDBJ accession numbers (slpA sequence type)
for the slpA genes reported in this study are AB249985 (gr-02),
LC003024 (yok-05), AB534595 (hr-04), AB704921 (fr-07),
AB704922 (fr-08), AB704920 (fr-10), AB761399 (fr-11), AB819625
(fr-12), LC003023 (fr-16), LC066519 (ar-01), AB533281 (08162-
01), LC066520 (j52-01), AB770148 (ac12056-01), AB770151
(cc12078-01), AB819404 (y05-02) and AB770145 (y02-01).
One supplementary table is available with the online Supplementary
Material.
M. Senoh and others
2 Journal of Medical Microbiology 00
Journal of Medical Microbiology jmmjmm000149.3d 26/8/2015 19:46:37
Antimicrobial susceptibility testing. Isolates were tested for sus-
ceptibility to gatifloxacin, moxifloxacin, erythromycin, clindamycin,
rifampicin, vancomycin and metronidazole by using Etest strips
(SYSMEX-bioMe´rieux) according to the manufacturer’s instructions.
The breakpoints used were 8 mg ml21 for gatifloxacin, moxifloxacin,
erythromycin and clindamycin, 16 mg ml21 for vancomycin, and
32 mg ml21 for rifampicin and metronidazole. Breakpoints for the
interpretation of susceptibility test results of moxifloxacin, clin-
damycin and metronidazole were available from the Clinical and
Laboratory Standards Institute (CLSI, 2014). The CLSI breakpoint for
anaerobes against moxifloxacin was used for the breakpoint against
gatifloxacin (CLSI, 2014). The MIC results for erythromycin, rifam-
picin and vancomycin were interpreted as previously described
(Spigaglia et al., 2011; Tenover et al., 2012).
RESULTS
Typing results of isolates recovered from
non-outbreak settings
Of the 120 isolates which came from 15 hospitals in non-
outbreak settings, 96 (80.0 %) isolates were A+B+CDT2
and 19 (15.8 %) were A2B+CDT2. The remaining 5
(4.2 %) isolates were identified as toxin-A-positive, toxin-
B-positive, CDT-positive (A+B+CDT+). These 120 isolates
were assigned to 24 PCR ribotypes, and to 19 slpA sequence
major types and 29 slpA sequence subtypes (Table S1 avail-
able in the online Supplementary Material). PCR-ribotype
smz (A+B+CDT2) was most disseminated and accounted
for 34.2 % of isolates (41/120) (Table 1); at least one isolate
of this type was found in each of the 15 hospitals examined.
We found a variant of PCR-ribotype smz, whose ribotype
pattern was nearly identical with that of type smz but
different in more than one band (Fig. 1). Thus, we
termed it type ysmz. Isolates of both smz and ysmz ribo-
types were classified into the same major slpA sequence
type. The PCR-ribotype ysmz was recovered only at hospi-
tal N in a non-outbreak setting in 2013, and during the
outbreak period in 2009 (Table 1). Of the 120 isolates, 47
(39.2 %) were PCR-ribotype smz or ysmz, and these isolates
were assigned to three slpA sequence subtypes (smz-01,
smz-02 and smz-03), with subtype smz-01 being most
common. All 19 A2B+CDT2 isolates were PCR-ribotype
trf (Fig. 1) and slpA sequence major type fr, and were further
assigned to six different slpA sequence subtypes. Sixteen
(13.3 %) and 13 (10.8 %) isolates were PCR-ribotypes 002
and 014, respectively. PCR-ribotypes smz, ysmz, trf, 002
and 014 together accounted for 79.2 % of isolates (95/120),
and the remaining 25 isolates were typed into 19 and 16
different PCR ribotypes and slpA sequence types, respectively
(Tables S1 and 1). Among five A+B+CDT+ isolates, five
different PCR ribotypes including types 019, 027 and 078
were identified. The PCR ribotype pattern of one isolate
was nearly identical with that of the reference strain (strain
CA8), characterized previously as PCR-ribotype 056 (Kill-
gore et al., 2008), but was different in more than one band
(PCR-ribotype c056 in Table S1). This isolate had the slpA
gene, the sequence of which was identical to that of strain
CA8 (slpA sequence type y02-01).
Typing results of isolates recovered in outbreak
settings
The 21 isolates from hospital L in an outbreak period were
assigned to four PCR ribotypes (014, smz, trf and sc1026)
and six slpA sequence types (Tables S1 and 1). Of those iso-
lates recovered from CDI patients hospitalized in six wards
during a four-week period, 13/21 (61.9 %) came from CDI
patients at one ward. Out of the 13 isolates from the ward,
eight, four and one were classified into PCR-ribotype smz/
slpA sequence type smz-01, trf/fr-12 and trf/fr-01, respect-
ively. The slpA sequence type fr-12 was not found among
the 120 isolates obtained at the 15 hospitals, including hos-
pital L, in non-outbreak settings. CDI due to PCR-ribotype
Table 1. Distribution of prevalent PCR ribotypes recovered from 15 hospitals in non-outbreak settings and 2 hospitals in outbreak
settings
Japan-ribotype PCR-ribotype Toxin production* No. of isolates (%) recovered
from 15 hospitals in
non-outbreak settings
No. of isolates (%) in an
outbreak setting at:
Hospital L Hospital N
yokD 002 A+B+CDT2 16 (13.3) 0 0
hrD 014 A+B+CDT2 13 (10.8) 5 (23.8) 0
smz 018 A+B+CDT2 41 (34.2) 9 (42.9) 1 (5.6)
ysmz 0189 A+B+CDT2 6 (5.0) 0 8 (44.4)
frD 017 A2B+CDT2 0 0 0
trf 369 A2B+CDT2 19 (15.8) 6 (28.6) 9 (50.0)
Other types 25 (20.8) 1 (4.8) 0
Total no. of isolates
tested
120 21 18
*A
+B+CDT2, toxin-A-positive, toxin-B-positive, binary-toxin-negative; A2B+CDT2, toxin-A-negative, toxin-B-positive, binary-toxin-negative.
DThe nomenclature of Japan-ribotypes was used in previous studies (Iwashima et al., 2010; Kato et al., 2001a, b; Sawabe et al., 2007).
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014 was found in the wards other than the one where smz/
smz-01 and trf/fr-14 were epidemic.
Among the 18 C. difficile isolates recovered from six wards
of hospital N during an outbreak of CDI, there were two
predominant types, PCR-ribotype trf/slpA sequence type
fr-01 (9 isolates) and type ysmz/smz-01 (8 isolates)
(Tables S1 and 1). The remaining one isolate was found
to be type smz/smz-01. Both trf/fr-01 and ysmz/smz-01
isolates were disseminated across four and five distinct
wards, respectively. Isolation of PCR-ribotype ysmz was
restricted to hospital N and this isolate was observed in
six of 10 isolates recovered during an endemic period
later on.
Analysis of isolates identified as types smz, ysmz
and trf by the Japan ribotyping scheme
Since PCR-ribotypes smz/ysmz and PCR-ribotype trf
accounted for a significant proportion of clinical isolates
in this and previous studies in Japan (Kato et al., 2001a,
2010; Sawabe et al., 2007; Iwashima et al., 2010), they
were further analysed at LCL. We later identified Japan-
ribotype smz as being PCR-ribotype 018 and replicated a
minor band variation between ribotypes smz and ysmz,
which was termed PCR-ribotype 0189
;
. Since Japan-
ribotype trf did not match any known reference strains
from the LCL library, further investigation of the trf
strain was conducted by Dr V. Hall (Public Health
Wales, Cardiff, UK); a novel ribotype was assigned, here
designated PCR-ribotype 369.
Antimicrobial susceptibility results
The MIC results of gatifloxacin, moxifloxacin, erythromy-
cin, clindamycin, rifampicin, vancomycin and
metronidazole for C. difficile stratified according to PCR
ribotype in non-outbreak settings and in outbreak settings
are shown in Tables 2 and 3, respectively. PCR-ribotypes
smz and ysmz are presented together in Tables 2 and 3.
Resistance to gatifloxacin, moxifloxacin, erythromycin
and clindamycin was observed in 100 %, 95.7 %, 100 %
and 97.9 % of PCR-ribotype smz/ysmz isolates collected
from 15 hospitals, respectively. All PCR-ribotype smz/
ysmz isolates from two hospitals in outbreak settings
were resistant to gatifloxacin, moxifloxacin, erythromycin
and clindamycin. Among 19 trf isolates from 15 hospitals
in non-outbreak settings, 17 (89.5 %) and 13 (68.4 %)
were resistant to gatifloxacin and moxifloxacin, respect-
ively. These 19 trf isolates were all resistant to erythromycin
and clindamycin. All of the 15 trf isolates (6 from hospital
L and 9 from hospital N) recovered from outbreak settings
were resistant to gatifloxacin. Among six trf isolates from
hospital L in an outbreak period, MICs of moxifloxacin
were 6 mg ml21 and 8 mg ml21 in four and two isolates,
respectively. Of nine trf isolates from hospital N in an out-
break period, eight were resistant to moxifloxacin; the MIC
of the remaining one was 6 mg ml21. High resistance to
both erythromycin and clindamycin was present in the
15 trf isolates prevalent at hospitals L and N; the MIC
value of all 15 isolates was more than 256 mg ml21. Resist-
ance to gatifloxacin, moxifloxacin, erythromycin and clin-
damycin was observed sporadically in 002 isolates
examined in this study. In PCR-ribotype 014 isolates recov-
ered in both non-outbreak settings and outbreak settings,
resistance to gatifloxacin, moxifloxacin, erythromycin and
clindamycin was less common. Rifampicin resistance
(MIC w32 mg ml21) was observed in only one isolate,
which was typed as PCR-ribotype og39/slpA sequence
type og39-01. This isolate was highly resistant to erythro-
mycin and clindamycin, but susceptible to gatifloxacin
and moxifloxacin. All 159 isolates examined had
600 bp
300 bp
M M M i jg ha b c d e f
Fig. 1. Representative PCR ribotype patterns of C. difficile isolates. Lanes: M, 100 bp ladder as a molecular mass marker; a,
PCR ribotype og39; b, type 001; c, type 002; d, type 014; e, type 0189 (ysmz); f, type 018 (smz); g, type 017; h, type 369
(trf); i, type 027; j, type 078.
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vancomycin MIC values distributed over a narrow range
(0.19–1 mg ml21). The metronidazole MIC was
j0.5 mg ml21 for all the isolates. One isolate was identified
as PCR-ribotype 027 and was susceptible to all seven anti-
microbial agents tested. The PCR-ribotype 078 isolate
recovered in this study was highly resistant to erythromy-
cin, but susceptible to the other six agents.
CDI due to predominant PCR ribotypes
The mean age of CDI patients due to PCR-ribotypes smz/
smz, trf, 014 and 002 was 77.4, 77.6, 71.9, and 74.0 years
old, respectively, and the difference in the four types was
not significant. The data for CDI therapy was available in
153 of the 159 patients. While 31 (20.3 %) patients had
no antibiotic treatment, 74 (48.4 %), 43 (28.1 %) and 5
(3.3 %) were treated with vancomycin, metronidazole
and both, respectively. No significant correlation was
found between the CDI treatments and PCR-ribotypes
(data not shown). Ten of the 159 patients underwent an
endoscopic examination and pseudomembranous colitis
(PMC) was found in three patients, who were infected by
PCR-ribotypes smz, 002 or 001. Two patients suffered
from CDI with severe complications; one patient with
type smz died of CDI and a pathological autopsy revealed
PMC, and another patient with type 002 survived after
emergency colectomy and was diagnosed with PMC
during the surgery.
DISCUSSION
PCR-ribotype smz designated by the Japan typing scheme
was found to correspond to PCR-ribotype 018 in the pre-
sent study. PCR-ribotypes 018 (smz)/0189 (ysmz) were
identified as the most common circulating strains
(39.2 %), and were disseminated across 15 hospitals exam-
ined. Also, types 018 (smz) and 0189 (ysmz) caused
outbreaks at two hospitals, highlighting a major epidemio-
logical role of them in both epidemic and endemic CDI in
Japan. Of 365 isolates obtained from 26 European
countries in 2008, 23 (6 %) were assigned as PCR-ribotype
018, 19 of which were recorded in Italy (Bauer et al., 2011).
In a more recent study from 20 European countries, PCR-
ribotype 018 was one of the ten most common types,
although distribution of 018 was not mentioned (Davies
et al., 2014). In Italy, PCR-ribotype 018 C. difficile was pre-
dominant in 2007 and 2008, superseding an other type
(PCR-ribotype 126), which was the most predominant
strain until 2005 (Spigaglia et al., 2010); from 2012 to
2014, 20 % of isolates from Italy were identified as type
018 (Freeman et al., 2015). A recent prospective study
showed that PCR-ribotype 018 was also the predominant
strain (48.1 %) at three hospitals in Korea from 2011 to
2012 (Han et al., 2014). Conversely, it was documented
that type 018 was not prevalent in England (Wilcox
et al., 2012) and the USA (Tickler et al., 2014). In Japan,
there have been historical reports suggesting a high
prevalence of PCR-ribotype 018 since the 1990s, when it
was already identified as the most prevalent strain at
three Japanese hospitals between 1996 and 1999 (Kato
et al., 2001a) and at four other sites between 2003 and
2007 (Kato et al., 2010). An independent epidemiological
study at another hospital in Japan showed that PCR-ribo-
type 018 replaced PCR-ribotype 014 as the most predomi-
nant strain over a five-year period from 2000 to 2004
(Sawabe et al., 2007). A similar shift was observed at a hos-
pital in Korea, where PCR-ribotype 018 has been identified
since 2006, and became more prevalent than PCR-ribotype
001 over a 10-year period between 2000 and 2009 (Lee
et al., 2014). Interestingly, in a healthy volunteer study in
Japan, 1234 individuals were examined and 94 (7.6 %)
were found to be colonized by C. difficile, but none of
them carried type 018 isolates in their intestinal tract
(Kato et al., 2001b). Isolation of PCR-ribotype 018
C. difficile from edible bivalve molluscs (Pasquale et al.,
2012) and poultry (Janezic et al., 2014) has been reported,
suggesting that food intake may constitute an important
route of C. difficile infection. Further molecular studies
on community-acquired CDI and food surveillance are
required in Japan.
In the present study, we identified PCR-ribotype 0189
(ysmz), which had a ribotype pattern shared by most
bands of type 018 (smz), and all type 0189 isolates tested
in the present study displayed slpA sequence type smz-01.
The type 0189 strain was exclusive to hospital N and was
recovered in both an outbreak period (2009) and a non-
outbreak setting (2012–2013), suggesting that the 0189
might have persisted within CDI inpatients, asymptomatic
carriers and/or in inanimate environments at hospital L for
years. More recently, the emergence of PCR-ribotype 356
has been noted in Italy, and it was postulated that this is
likely a strain subtype that may have evolved from the
main PCR-ribotype 018 lineage (Freeman et al., 2015).
Albeit ribotype profiles of types 0189 (ysmz) and 356
have not been compared directly, it is epidemiologically
significant that strain variants similar to ribotype 018
emerged in independent areas where this strain was
predominant.
An early report showed that PCR riboype 018 has been an
endemic strain since the 1990s in Japan (Kato et al., 2001a),
suggesting that 018 and its variants might have spread from
Asia, including Japan, to other countries. More compre-
hensive studies at a whole genome sequencing level on
types 018/ 0189 in Asia and type 018/356 in Europe are
required to unveil its evolution pattern and potential of
acquired functional mechanisms in order to understand
their global spread and epidemiology.
High rates of resistance to gatifloxacin, moxifloxacin, ery-
thromycin and clindamycin in both PCR-ribotype 018
and 0189 isolates were observed, although they both
remained susceptible to rifampicin. In Italy, resistance
against fluoroquinolones in type 018 isolates has been
documented (Spigaglia et al., 2010; Freeman et al., 2015).
Prevalent ribotypes of C. difficile in Japan
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In a Korean study, eight isolates belonging to type 018 were
tested and all of them had high overall resistance against
several antibiotics including moxifloxacin, erythromycin
and clindamycin (Lee et al., 2014). Sawabe et al. (2007)
reported that all type 018 isolates at their hospital in
Japan were resistant to gatifloxacin and moxifloxacin, as
well as clindamycin, and that the noticeable shift in ende-
mic strain from type 014 to type 018 may have been related
to the introduction of gatifloxacin to their hospital in 2002.
He et al. (2013) documented that the acquisition of resist-
ance to commonly used antibiotics (fluoroquinolones) is a
major feature of the continued evolution and persistence of
C. difficile BI/NAP1/027 in healthcare settings. In this
study, we found only one type 027 isolate, which was sus-
ceptible to new fluoroquinolones. In Japan, while some
reports have shown sporadic cases including one with ful-
minant colitis due to PCR-ribotype 027 C. difficile (Kato
et al., 2007; Sawabe et al., 2007; Nishimura et al., 2014),
no outbreaks associated with type 027 have been reported
so far. It is unknown why the nosocomial spread of 027
C. difficile resistant to fluoroquinolones has not been
found in Japan, where type 018 resistant to fluoroquino-
lones has been distributed to a number of hospitals. Simi-
larly, PCR-ribotype 078 C. difficile was isolated from only
one patient in the present study, while this strain has
been reported to be recovered more frequently from ani-
mals in Japan (Niwa et al., 2013; Usui et al., 2014). The
lower frequency of isolation, either of PCR-ribotype 027
or 078 from CDI in human in Asian countries including
Japan (Cheng et al., 2011; Han et al., 2014), may reflect
differences in the intestinal ecosystem and/or immunologi-
cal responses between Asian populations and those of
countries where 027 or 078 have become predominant.
Freeman et al. (2015) documented that all ribotype 018
and 356 isolates obtained from Italy were resistant to
rifampicin, but rifampicin resistance was not observed in
type 018/0189 isolates examined in our study. Also, Free-
man et al. (2015) showed that vancomycin MICs were
higher among 018 and 356 with geometric mean MICs of
2.00 mg ml21 and 2.28 mg ml21, respectively, compared
with those of the remaining common ribotypes; geometric
mean MICs of metronidazole were elevated in ribotype 027
(1.42 mg ml21) and ribotype 356 (0.61 mg ml21) isolates
(Freeman et al., 2015). Tickler et al. (2014) observed
reduced susceptibility to vancomycin in 39.2 % of 027 iso-
lates collected from US hospitals. In our study, none of the
isolates tested including type 018/0189 showed reduced sus-
ceptibility to vancomycin and metronidazole. The potential
emergence of increasing resistance to vancomycin and
metronidazole may warrant further monitoring of MICs
of the agents especially in type 018/0189 isolates in Japan.
In contrast, the emergence of A2B+ isolates, which have
1.8 kbp deletions in the repeating sequences in tcdA and
belong to toxinotype VIII, has been reported in Japan as
well as the Netherlands, Ireland, Poland, Korea, China
and Argentina (Kuijper et al., 2001; Komatsu et al., 2003;
Drudy et al., 2007; Shin et al., 2008; Goorhuis et al.,
2009, Kato et al., 2010; Pituch et al., 2011; Hawkey et al.,
2013). The reports from all these countries except Japan
documented that the vast majority of these A2B+ isolates
were found to be of PCR-ribotype 017 (Kuijper et al.,
2001; Drudy et al., 2007; Goorhuis et al., 2009; Pituch
et al., 2011; Hawkey et al., 2013; Lee et al., 2014). PCR-
ribotype 017 was identified in 4 % of isolates from 34 Euro-
pean countries (Davies et al., 2014) and 2.2 % of isolates
from 32 hospitals in the USA (Tickler et al., 2014).
Although we have reported the isolation of PCR-ribotype
017 from sporadic cases (Kato et al., 2001b, 2010; Iwashima
et al., 2010) in Japan, notably, all 34 A2B+ isolates collected
in the present study were typed as Japan-ribotype trf, which
corresponded neither to type 017 nor 047, and was newly
assigned as PCR-ribotype 369. In this study, type 369 was
the second most frequent ribotype (15.8 %) among 120
isolates from 15 hospitals in non-outbreak settings, and
was also prevalent at two hospitals during outbreak
periods. The type 369 strain was reported to be blamed
for outbreaks that occurred at Japanese hospitals in 2000
and 2001 (Komatsu et al., 2003; Sato et al., 2004); ribotype
369 has been identified as an epidemic strain since the early
2000s in Japan. Both PCR-ribotype 017 and 369 isolates
tested had identical deletions at the repeating sequences
in tcdA and a nonsense mutation introducing a stop
codon at amino acid position 47 of tcdA (data not
shown), and were classed as slpA sequence major type fr.
This suggests that types 017 and 369 are not phylogeneti-
cally distant to each other and they may share a common
recent ancestor, though deep genome sequencing has not
been performed yet. Evolutionary comparative analysis
and determination of exclusive factors to each strain will
allow understanding of the preferential establishment of
one or another, such as of 369 in Japan and type 017 in
Europe. High resistance against erythromycin and clinda-
mycin was observed in all type 369 isolates tested, which
is consistent with the previous reports on type 017 strains
(Kuijper et al., 2001; Pituch et al., 2011; Lee et al., 2014;
Freeman et al., 2015). In addition, 94.1 % (32/34) and
67.6 % (23/34) of type 369 isolates examined by this
study were resistant to gatifloxacin and moxifloxacin,
respectively. Resistance against new fluoroquinolones in
PCR-ribotype 017 was also reported from other countries
(Pituch et al., 2011; Spigaglia et al., 2011; Lee et al., 2014;
Freeman et al., 2015), indicating the need of escalating
attention to isolates belonging to toxinotype VIII, which
have been showing multi-resistance tendencies.
It was reported that PCR-ribotype 002 constituted approxi-
mately 5 % of isolates from European countries in 2008,
and 3.5 % of isolates from US hospitals between 2011
and 2013 (Bauer et al., 2011; Tickler et al., 2014). The sig-
nificant increase in the prevalence of type 002 from 3 %
(2007–2008) to 6 % (2009–1010) was documented in Eng-
land (Wilcox et al., 2012). Moreover, PCR-ribotype 002
was reported to be the most prevalent type (10.1 %) in a
healthcare region in Hong Kong (Cheng et al., 2011).
In Japan, PCR-ribotype 002 was the third most frequently
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found (13.3 %) in the present study, and a three-year
investigation at a university hospital in Japan showed
that type 002 was one of the three most prevalent types
(19.7 %) (Iwashima et al., 2010). In addition, Tenover
et al. (2010) reported< that the sensitivity of the enzyme
immunoassay (EIA) was significantly lower for detecting
toxins from specimens of CDI infected by ribotype 002,
suggesting that these cases may be overlooked when diag-
nosed by EIA for toxins only. More studies of worldwide
variation and differences in prevalence and disease severity
by type 002 are required.
PCR-ribotype 014 has been reported to be one of the most
common PCR ribotypes in the world (Kato et al., 2001a,
2010; Iwashima et al., 2010; Bauer et al., 2011; Cheng
et al., 2011; Wilcox et al., 2012; Davies et al., 2014; Freeman
et al., 2014; Han et al., 2014; Tickler et al., 2014). In the
present study, 10.8 % (13/120) of the isolates recovered
in non-outbreak settings and= 19.0 % (4/21) of the isolates
recovered in an outbreak period at hospital L were typed
as PCR-ribotype 014. Moreover, a previous study showed
that PCR-ribotype 014 was in fact the most frequently iso-
lated strain from healthy Japanese individuals; of 94 indi-
viduals positive for C. difficile-culture, 17 of them
(18.0 %) had this type (Kato et al., 2001b). Janezic et al.
(2014) documented that PCR-ribotype 014 was the
second most prevalent strain following type 078 among
animal isolates and also had a broader range of animal
hosts. In our study, the resistance of PCR-ribotype 014 to
gatifloxacin, moxifloxacin, erythromycin and clindamycin
was less common, consistent with the results of other
reports (Tickler et al., 2014; Freeman et al., 2015). The abil-
ity to colonize a variety of hosts including humans may be
responsible for its relatively high nosocomial and commu-
nity prevalence (Janezic et al., 2014).
Our study showed no difference in the mean age of CDI
patients due to strains 018, 369, 002 or 014. Also, we
found no significant correlation between the CDI treat-
ments and PCR ribotypes. Since only limited data about
clinical features of patients, such as presence of comorbid-
ities, symptoms and outcomes including recurrences was
available, neither potential risk factors for CDI due to pre-
dominant types nor specific correlation between outcomes
and type differences could be clarified in this study. It was
reported that PCR-ribotype 018 was significantly associated
with complicated disease outcome (Bauer et al., 2011). Pro-
spective studies are needed to elucidate the involvement of
these types with CDI progression and clinical outcomes.
In summary, PCR-ribotypes 018 (smz)/0189 (ysmz), 369
(trf), 002 and 014 were identified as the major types circu-
lating in Japan. Particularly, types 018/ 0189 and 369 were
found to be prevalent and associated with both epidemic
and endemic CDI in Japan. A European study demon-
strated that increased awareness of CDI and the use of opti-
mal testing methods could reduce the dissemination of
epidemic strains (Davies et al., 2014). The high epidemicity
of ribotypes 018 and 369 and a lower diversity of ribotypes
observed in the present study may reflect the insufficient
awareness of CDI and a suboptimal test-density in Japan.
Further studies are warranted to understand the epidemio-
logical relevance and the role of these strains in relation to
their spread and prevalence nationwide and globally.
ACKNOWLEDGEMENTS
We thank Dr V. Hall (Public Health Wales, Cardiff, UK) for analysing
ribotype 369 (trf) isolate and Dr S. Suzuki (National Institute of
Infectious Diseases, Tokyo, Japan) for her helpful comments. The
technical assistance of S. Yonamine, K. Kai, Y. Taki, and
Y. Yoshimura is gratefully acknowledged. This work was supported
by a grant (Research Program on Emerging and Re-emerging Infec-
tious Diseases) from Japan Agency for Medical Research and Devel-
opment, AMED. The authors declare no conflicts of interest.
REFERENCES
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S.,
Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T. & Kuijper,
E. J. (2011). ECDIS Study Group Clostridium difficile infection in
Europe: a hospital-based survey. Lancet 377, 63–73.
Cheng, V. C., Yam, W. C., Lam, O. T., Tsang, J. L., Tse, E. Y., Siu, G. K.,
Chan, J. F., Tse, H., To, K. K. & other authors (2011). Clostridium
difficile isolates with increased sporulation: emergence of PCR
ribotype 002 in Hong Kong. Eur J Clin Microbiol Infect Dis 30,
1371–1381.
CLSI (2014). Performance Standards for AntimicrobialSsusceptibility
Testing; 24th Informational Supplement M100–S24. Wayne, PA:
Clinical and Laboratory Standards Institute.
Davies, K. A., Longshaw, C. M., Davis, G. L., Bouza, E., Barbut, F.,
Barna, Z., Delme´e, M., Fitzpatrick, F., Ivanova, K. & other authors
(2014). Underdiagnosis of Clostridium difficile across Europe: the
European, multicentre, prospective, biannual, point-prevalence
study of Clostridium difficile infection in hospitalised patients with
diarrhoea (EUCLID). Lancet Infect Dis 14, 1208–1219.
Drudy, D., Harnedy, N., Fanning, S., O’Mahony, R. & Kyne, L. (2007).
Isolation and characterisation of toxin A-negative, toxin B-positive
Clostridium difficile in Dublin, Ireland. Clin Microbiol Infect 13,
298–304.
Freeman, J., Vernon, J., Morris, K., Nicholson, S., Todhunter, S.,
Longshaw, C. & Wilcox, M. H. (2015). Pan-European Longitudinal
Surveillance of Antibiotic Resistance among Prevalent Clostridium
difficile Ribotypes’ Study Group Pan-European longitudinal
surveillance of antibiotic resistance among prevalent Clostridium
difficile ribotypes. Clin Microbiol Infect 21, 248.
Goorhuis, A., Bakker, D., Corver, J., Debast, S. B., Harmanus, C.,
Notermans, D. W., Bergwerff, A. A., Dekker, F. W. & Kuijper, E. J.
(2008). Emergence of Clostridium difficile infection due to a new
hypervirulent strain, polymerase chain reaction ribotype 078. Clin
Infect Dis 47, 1162–1170.
Goorhuis, A., Legaria, M. C., van den Berg, R. J., Harmanus, C.,
Klaassen, C. H., Brazier, J. S., Lumelsky, G. & Kuijper, E. J. (2009).
Application of multiple-locus variable-number tandem-repeat
analysis to determine clonal spread of toxin A-negative Clostridium
difficile in a general hospital in Buenos Aires, Argentina. Clin
Microbiol Infect 15, 1080–1086.
Han, S. H., Kim, H., Lee, K., Jeong, S. J., Park, K. H., Song, J. Y., Seo,
Y. B., Choi, J. Y., Woo, J. H. & other authors (2014). Epidemiology and
Prevalent ribotypes of C. difficile in Japan
http://jmm.sgmjournals.org 9
Journal of Medical Microbiology jmmjmm000149.3d 26/8/2015 19:46:48
clinical features of toxigenic culture-confirmed hospital-onset
Clostridium difficile infection: a multicentre prospective study in
tertiary hospitals of South Korea. J Med Microbiol 63, 1542–1551.
Hawkey, P. M., Marriott, C., Liu, W. E., Jian, Z. J., Gao, Q., Ling, T. K.,
Chow, V., So, E., Chan, R. & other authors (2013). Molecular
epidemiology of Clostridium difficile infection in a major Chinese
hospital: an underrecognized problem in Asia? J Clin Microbiol 51,
3308–3313.
He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D. J., Martin,
M. J., Connor, T. R., Harris, S. R., Fairley, D. & other authors
(2013). Emergence and global spread of epidemic healthcare-
associated Clostridium difficile. Nat Genet 45, 109–113.
Iwashima, Y., Nakamura, A., Kato, H., Wakimoto, Y., Wakiyama, N.,
Kaji, C. & Ueda, R. (2010). A retrospective study of the
epidemiology of Clostridium difficile infection at a University
Hospital in Japan: genotypic features of the isolates and clinical
characteristics of the patients. J Infect Chemother 16, 329–333.
Janezic, S., Zidaric, V., Pardon, B., Indra, A., Kokotovic, B., Blanco,
J. L., Seyboldt, C., Diaz, C. R., Poxton, I. R. & other authors (2014).
International Clostridium difficile animal strain collection and large
diversity of animal associated strains. BMC Microbiol 14, 173–183.
Kato, H., Kato, N., Watanabe, K., Yamamoto, T., Suzuki, K., Ishigo, S.,
Kunihiro, S., Nakamura, I., Killgore, G. E. & Nakamura, S. (2001a).
Analysis of Clostridium difficile isolates from nosocomial outbreaks
at three hospitals in diverse areas of Japan. J Clin Microbiol 39,
1391–1395.
Kato, H., Kita, H., Karasawa, T., Maegawa, T., Koino, Y., Takakuwa,
H., Saikai, T., Kobayashi, K., Yamagishi, T. & Nakamura, S.
(2001b). Colonisation and transmission of Clostridium difficile in
healthy individuals examined by PCR ribotyping and pulsed-field
gel electrophoresis. J Med Microbiol 50, 720–727.
Kato, H., Yokoyama, T., Kato, H. & Arakawa, Y. (2005). Rapid and
simple method for detecting the toxin B gene of Clostridium difficile
in stool specimens by loop-mediated isothermal amplification.
J Clin Microbiol 43, 6108–6112.
Kato, H., Ito, Y., van den Berg, R. J., Kuijper, E. J. & Arakawa, Y.
(2007). First isolation of Clostridium difficile 027 in Japan. Euro
Surveill 12, E070111.3.
Kato, H., Kato, H., Ito, Y., Akahane, T., Izumida, S., Yokoyama, T.,
Kaji, C. & Arakawa, Y. (2010). Typing of Clostridium difficile isolates
endemic in Japan by sequencing of slpA and its application to
direct typing. J Med Microbiol 59, 556–562.
Killgore, G., Thompson, A., Johnson, S., Brazier, J., Kuijper, E., Pepin,
J., Frost, E. H., Savelkoul, P., Nicholson, B. & other authors (2008).
Comparison of seven techniques for typing international epidemic
strains of Clostridium difficile: restriction endonuclease analysis,
pulsed-field gel electrophoresis, PCR-ribotyping, multilocus
sequence typing, multilocus variable-number tandem-repeat
analysis, amplified fragment length polymorphism, and surface layer
protein A gene sequence typing. J Clin Microbiol 46, 431–437.
Komatsu, M., Kato, H., Aihara, M., Shimakawa, K., Iwasaki, M.,
Nagasaka, Y., Fukuda, S., Matsuo, S., Arakawa, Y. & other authors
(2003). High frequency of antibiotic-associated diarrhea due to toxin
A-negative, toxin B-positive Clostridium difficile in a hospital in Japan
and risk factors for infection. Eur J ClinMicrobiol Infect Dis 22, 525–529.
Kuijper, E. J., de Weerdt, J., Kato, H., Kato, N., van Dam, A. P., van der
Vorm, E. R., Weel, J., van Rheenen, C. & Dankert, J. (2001).
Nosocomial outbreak of Clostridium difficile-associated diarrhoea
due to a clindamycin-resistant enterotoxin A-negative strain. Eur J
Clin Microbiol Infect Dis 20, 528–534.
Lee, J. H., Lee, Y., Lee, K., Riley, T. V. & Kim, H. (2014). The changes of
PCR ribotype and antimicrobial resistance of Clostridium difficile in a
tertiary care hospital over 10 years. J Med Microbiol 63, 819–823.
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan,
Y., Gorbach, S., Sears, P., Shue, Y. K. & OPT-80-003 Clinical Study
Group (2011). Fidaxomicin versus vancomycin for Clostridium
difficile infection. N Engl J Med 364, 422–431.
Miller, M., Gravel, D., Mulvey, M., Taylor, G., Boyd, D., Simor, A.,
Gardam, M., McGeer, A., Hutchinson, J. & other authors (2010).
Health care-associated Clostridium difficile infection in Canada:
patient age and infecting strain type are highly predictive of severe
outcome and mortality. Clin Infect Dis 50, 194–201.
Nishimura, S., Kou, T., Kato, H., Watanabe, M., Uno, S., Senoh, M.,
Fukuda, T., Hata, A. & Yazumi, S. (2014). Fulminant
pseudomembranous colitis caused by Clostridium difficile PCR ribotype
027 in a healthy young woman in Japan. J Infect Chemother 20, 729–731.
Niwa, H., Kato, H., Hobo, S., Kinoshita, Y., Ueno, T., Katayama, Y.,
Hariu, K., Oku, K., Senoh, M. & other authors (2013). Postoperative
Clostridium difficile infection with PCR ribotype 078 strain identified
at necropsy in five Thoroughbred racehorses. Vet Rec 173, 607–613.
Pasquale, V., Romano, V., Rupnik, M., Capuano, F., Bove, D., Aliberti,
F., Krovacek, K. & Dumontet, S. (2012). Occurrence of toxigenic
Clostridium difficile in edible bivalve molluscs. Food Microbiol 31,
309–312.
Pituch, H., Obuch-Woszczatyn´ski, P., Wultan´ska, D., Nurzyn´ska, G.,
Harmanus, C., Banaszkiewicz, A., Radzikowski, A., Łuczak, M., van
Belkum, A. & Kuijper, E. (2011). Characterization and antimicrobial
susceptibility of Clostridium difficile strains isolated from adult
patients with diarrhoea hospitalized in two university hospitals in
Poland, 2004-2006. J Med Microbiol 60, 1200–1205.
Sato, H., Kato, H., Koiwai, K. & Sakai, C. (2004). [A nosocomial
outbreak of diarrhea caused by toxin A-negative, toxin B-positive
Clostridium difficile in a cancer center hospital]. Kansenshogaku
Zasshi 78, 312–319 (in Japanese).
Sawabe, E., Kato, H., Osawa, K., Chida, T., Tojo, N., Arakawa, Y. &
Okamura, N. (2007). Molecular analysis of Clostridium difficile at a
university teaching hospital in Japan: a shift in the predominant type
over a five-year period. Eur J Clin Microbiol Infect Dis 26, 695–703.
Shin, B. M., Kuak, E. Y., Yoo, H. M., Kim, E. C., Lee, K., Kang, J. O.,
Whang, D. H. & Shin, J. H. (2008). Multicentre study of the
prevalence of toxigenic Clostridium difficile in Korea: results of a
retrospective study 2000–2005. J Med Microbiol 57, 697–701.
Spigaglia, P., Barbanti, F., Dionisi, A. M. & Mastrantonio, P. (2010).
Clostridium difficile isolates resistant to fluoroquinolones in Italy:
emergence of PCR ribotype 018. J Clin Microbiol 48, 2892–2896.
Spigaglia, P., Barbanti, F., Mastrantonio, P., Ackermann, G.,
Balmelli, C., Barbut, F., Bouza, E., Brazier, J., Delmee, M. & other
authors (2011). Multidrug resistance in European Clostridium
difficile clinical isolates. J Antimicrob Chemother 66, 2227–2234.
Stubbs, S. L., Brazier, J. S., O’Neill, G. L. & Duerden, B. I. (1999). PCR
targeted to the 16S-23S rRNA gene intergenic spacer region of
Clostridium difficile and construction of a library consisting of 116
different PCR ribotypes. J Clin Microbiol 37, 461–463.
Stubbs, S., Rupnik, M., Gibert, M., Brazier, J., Duerden, B. & Popoff,
M. (2000). Production of actin-specific ADP-ribosyltransferase
(binary toxin) by strains of Clostridium difficile. FEMS Microbiol
Lett 186, 307–312.
Tenover, F. C., Novak-Weekley, S., Woods, C. W., Peterson, L. R.,
Davis, T., Schreckenberger, P., Fang, F. C., Dascal, A., Gerding,
D. N. & other authors (2010). Impact of strain type on detection
of toxigenic Clostridium difficile: comparison of molecular diagnostic
and enzyme immunoassay approaches. J Clin Microbiol 48, 3719–3724.
Tenover, F. C., Tickler, I. A. & Persing, D. H. (2012). Antimicrobial-
resistant strains of Clostridium difficile from North America.
Antimicrob Agents Chemother 56, 2929–2932.
M. Senoh and others
10 Journal of Medical Microbiology 00
Journal of Medical Microbiology jmmjmm000149.3d 26/8/2015 19:46:48
Tickler, I. A., Goering, R. V., Whitmore, J. D., Lynn, A. N., Persing,
D. H., Tenover, F. C. & Healthcare Associated Infection
Consortium (2014). Strain types and antimicrobial resistance
patterns of Clostridium difficile isolates from the United States,
2011 to 2013. Antimicrob Agents Chemother 58, 4214–4218.
Usui, M., Nanbu, Y., Oka, K., Takahashi, M., Inamatsu, T., Asai, T.,
Kamiya, S. & Tamura, Y. (2014). Genetic relatedness between
Japanese and European isolates of Clostridium difficile originating
from piglets and their risk associated with human health. Front
Microbiol 5, 513–521.
Walker, A. S., Eyre, D. W., Wyllie, D. H., Dingle, K. E., Griffiths, D.,
Shine, B., Oakley, S., O’Connor, L., Finney, J. & other authors
(2013). Relationship between bacterial strain type, host biomarkers,
and mortality in Clostridium difficile infection. Clin Infect Dis 56,
1589–1600.
Wilcox, M. H., Shetty, N., Fawley, W. N., Shemko, M., Coen, P., Birtles,
A., Cairns, M., Curran, M. D., Dodgson, K. J. & other authors (2012).
Changing epidemiology of Clostridium difficile infection following the
introduction of a national ribotyping-based surveillance scheme in
England. Clin Infect Dis 55, 1056–1063.
Prevalent ribotypes of C. difficile in Japan
http://jmm.sgmjournals.org 11
Journal of Medical Microbiology jmmjmm000149.3d 26/8/2015 19:46:48
Dear Authors,
Please ﬁnd enclosed a proof of your article for checking.
When reading through your proof, please check carefully authors’ names, scientiﬁc data, data in tables, any math-
ematics and the accuracy of references. Please do not make any unnecessary changes at this stage. All necess-
ary corrections should be marked on the proof at the place where the correction is to be made; please mark up
the correction in the PDF and return it to us (see instructions on marking proofs in Adobe Reader).
Any queries that have arisen during preparation of your paper for publication are listed below and indicated on the
proof.
Please provide your answers when returning your proof.
Please return your proof by email (sgmprod@charlesworth-group.com) within 2 days of receipt of this message.
Query no Query
1 Please check the use of a prime in PCR-ribotype 0189 and change to
an apostrophe in the text, figure legend and tables if necessary.
2 Please check that the date in reference citation Tenover et al. (2010)
is correct.
3 Please check the number of isolates recovered in an outbreak period
at hospital L and typed as PCR-ribotype 014.
Ordering reprints for SGM journals
As a result of declining reprint orders and feedback from many authors who tell us they
have no use for reprints, SGM no longer provides free reprints to corresponding authors;
instead, corresponding authors will receive two emails:
i) An email including a link to download the published PDF of their paper. You
can forward this link to co-authors or others, and they can also use it to
download the published PDF. The link can be used up to 25 times. This
email will be sent out at around the time your article is published online.
ii) An email including a link to the SGM Reprint Service. You can forward this
email to your co-authors if you wish, so that they can order their own reprints
directly, or to your finance or purchasing department, if orders are placed
centrally. This email will be sent out at around the time that your article is fina-
lized for printing.
When you click on the link in this second email, you will be taken to an order page to
place your reprint order. Like most online ordering sites, it is necessary to set up an
account and provide a delivery address while placing your order, if you do not already
have an account. Once an account and delivery address have been set up, these details
will be stored by the system for use with future orders. Payments can be made by credit
card, PayPal or purchase order.
As reprint orders are despatched by courier, there is a charge for postage and packing.
SUMMARY
N You can create or update your reprint account at any time at
http://sgm-reprints.charlesworth.com/
N You will be sent an email when the reprints of this paper are
ready for ordering
N You cannot order reprints of this paper before this email has
been sent, as your paper will not be in the system
N Reprints can be ordered at any time after publication
N You will also receive an email with a link to download the PDF of
your published paper
The reprint ordering details will be emailed to the author listed as the corresponding
author on the journal’s manuscript submission system. If your paper has been published
(the final version, not the publish-ahead-of-print version) but you have not received this
notification, email reprints@sgm.ac.uk quoting the journal, paper number and publication
details.
If you have any questions or comments about the reprint-ordering system or about the
link to your published paper, email reprints@sgm.ac.uk
